Related references
Note: Only part of the references are listed.Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
Claire N. Harrison et al.
LANCET HAEMATOLOGY (2017)
Development of TG101348 for the treatment of JAK2-driven malignancies
J. Hood et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells
Clodagh Keohane et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis
Catriona Jamieson et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
A. Pardanani et al.
BLOOD CANCER JOURNAL (2015)
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis A Randomized Clinical Trial
Animesh Pardanani et al.
JAMA ONCOLOGY (2015)
Effect of Food on the Bioavailability and Tolerability of the JAK2-Selective Inhibitor Fedratinib (SAR302503): Results From Two Phase I Studies in Healthy Volunteers
Meng Zhang et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2015)
A Randomized, Placebo-Controlled Study of the Pharmacokinetics, Pharmacodynamics, and Tolerability of the Oral JAK2 Inhibitor Fedratinib (SAR302503)in Healthy Volunteers
Meng Zhang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms
Olga Pozdnyakova et al.
MODERN PATHOLOGY (2014)
Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)
T. Zhou et al.
LEUKEMIA (2014)
The Janus Kinase 2 Inhibitor Fedratinib Inhibits Thiamine Uptake: A Putative Mechanism for the Onset of Wernicke's Encephalopathy
Qiang Zhang et al.
DRUG METABOLISM AND DISPOSITION (2014)
Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Animesh Pardanani et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations
A. Pardanani et al.
LEUKEMIA (2011)
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera
Gerlinde Werning et al.
CANCER CELL (2008)
Share Paper
